About Collate

Collate is an AI document generation platform for life sciences. We automate paperwork with AI, helping our customers get life-saving innovations to patients years faster. Collate is an end-to-end solution, powering every step of drug, diagnostic, and medical device development—from concept to market.

Our CEOSurbhi Sarna is a former General Partner at Y Combinator. Surbhi founded nVision Medical, which developed a new method to detect ovarian cancer and was acquired by Boston Scientific. Our CTONate Smith is a former Visiting Partner at Y Combinator and founder of Lever. Our AI researchers, engineers, and designers have worked at Google, Nvidia, Meta, Netflix, Amazon, AirBnB, Hippocratic AI, and Grail, and 40% of our team are former founders.

We’re an elite team, with $125M in funding from top investors (Redpoint, First Round Capital, CRV, Conviction, Y Combinator) and leaders in healthcare and AI. This is a rare chance to join an early-stage company with world-changing potential, experienced founders, and resources to execute at scale.

About the Role

Collate is the first of its kind for what we're building — no incumbent doing this today, and no established workflow to copy. That's the job: continue to define the roadmap for an AI category that doesn't exist yet, then build it.

You'll co-own the product surface end to end that lets the world's most regulated companies trust us with their most sensitive documents. You'll sit at the intersection of engineering and go-to-market, working directly with Surbhi (CEO) to turn what customers need into a roadmap the team can actually ship.

This is a rare seat: you're not maintaining an AI category, you're creating a new one. It's a role for someone who wants outsized ownership over how an early-stage company becomes the category leader without slowing down.

We are 5 days a week onsite in San Francisco.

What You'll Do

Define and drive the AI product strategy for Collate's capabilities for organizations operating under real regulatory pressure
Run point on the technical requirements and translate them into a roadmap engineering can build against
Work directly with regulatory and clinical teams at customer organizations to understand their workflows and compliance requirements at a granular level
Partner daily with engineering and design to scope, prioritize, and ship — this is a hands-on, in-the-weeds role
Define the metrics that matter for enterprise adoption, retention, and expansion, and use them to drive prioritization
Be the connective tissue between GTM, Sales, and Customer Success so the roadmap reflects what's actually closing and renewing deals
Represent the customer's voice in every cross-functional room you're in

What We're Looking For

7+ years of product management experience with a track record of shipping software
A builder's instinct — you'd rather be in the weeds with engineering than reviewing a roadmap deck
High agency and comfort with ambiguity; you can walk into a fast-moving, lightly-processed environment and bring structure without slowing anyone down
Genuine comfort working directly with founders and designers on 0-to-1 problems — you're energized by ambiguity, not looking for it to be resolved before you start and your communication style is clear and direct.
Strong plus: experience in life sciences, healthtech, or another regulated industry and real familiarity with regulatory, clinical, or pharma workflows

Why Join Collate?

Impact: Build systems and experiences that touch real patients and providers, improving healthcare outcomes.
Ownership: Shape both our product experience and our engineering culture from the start.
Learning: Collaborate with a uniquely interdisciplinary team—AI researchers, healthcare leaders, and experienced startup builders.
Upside: Join a company early enough to have meaningful equity and career-defining impact

The base salary range for this role is depending on experience and level (Tier 1, San Francisco)

PM: $181-225K; Senior PM: $210-253K; Staff PM: $237-295K

About the company

Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.

Company Size

11-50

Company Stage

Series B

Total Funding

$125M

Headquarters

San Francisco, California

Founded

2025

Get referred to Collate

See people who can refer or advise you

Simplify's Take

What believers are saying

Collate raised $95 million in June 2026 at nearly $1 billion valuation.
Management says 50% to 90% document time savings drives urgent budget approval.
AI paperwork demand is surging; Sarna expects most life-sciences companies to buy within nine months.

What critics are saying

Veeva’s June 2026 Vault AI and Falcon directly attack Collate’s core documentation workflow.
Life-sciences buyers already trust Veeva’s entrenched system, compressing Collate’s sales cycles in 2026.
If major pharmaceutical customers standardize on Veeva, Collate becomes a feature, not a company.

What makes Collate unique

Surbhi Sarna’s 2018 Boston Scientific exit and YC pedigree build instant life-sciences credibility.
Collate targets GxP documentation with human-in-loop audits, matching regulated workflow requirements.
The platform won 50 customers since May 2025, including pharma, device, and biotech firms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity
Flexible Work Hours
Professional Development Budget

Growth & Insights and Company News

6 month growth

35%

1 year growth

31%

2 year growth

CNBC

Jul 9th, 2026

Collate CEO Surbhi Sarna on AI software automating life-sciences documentation for drug approvals

Surbhi Sarna, CEO and founder of Collate, discussed her company's AI-native software that automates documentation for life-sciences companies bringing drugs and devices to market. The GxP-compliant platform maintains human oversight for audits. Sarna's journey into healthcare technology began as a teenager when she was hospitalised with debilitating ovarian cysts, facing uncertainty about whether she had cancer. This experience motivated her to found nVision Medical, which was later acquired by Boston Scientific. Collate addresses the extensive documentation requirements in the pharmaceutical and medical device industries, streamlining regulatory compliance processes whilst ensuring proper human verification remains in place.

Forbes

Jun 3rd, 2026

AI startup Collate raises $95M to automate life sciences paperwork at near-$1B valuation

AI startup Collate has raised $95 million in a Series C round led by Redpoint Ventures, valuing the company at nearly $1 billion. The funding brings total capital raised to $125 million since the San Francisco-based company emerged from stealth 17 months ago. Founded by two-time entrepreneur and former Y Combinator partner Surbhi Sarna, Collate automates paperwork for life sciences companies, including regulatory filings and clinical trial documentation. The startup has signed approximately 50 customers since May 2025, including major pharmaceutical companies and medical device manufacturers. Collate's AI tools deliver time savings of 50% to 90% on documents that previously took months to complete, whilst maintaining accuracy above 90%. The company requires human verification before documents are exported to ensure patient safety.

American Bazaar, Inc.

Jan 21st, 2025

Collate secures $30M to automate paperwork

Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.